CoChat
Sign Up
Cited by 76Folate and B Vitamins ResearchParkinson's Disease Mechanisms and TreatmentsMetabolism and Genetic Disorders

Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease

dos Santos, Eliseu Felippe, Busanello, Estela Natacha Brandt, Miglioranza, Anelise, Zanatta, Ângela, Barchak, Alethea Gatto, Vargas, Carmen Regla, Saute, Jonas, Rosa, Charles +7 more·2009·Metabolic Brain Disease
DOI 10.1007/s11011-009-9139-4
Open this paper in CoChat — free account

Abstract

In the present work we measured blood levels of total homocysteine ((t)Hcy), vitamin B(12) and folic acid in patients with Parkinson s disease (PD) and in age-matched controls and searched for possible associations between these levels with smoking, alcohol consumption, L-DOPA treatment and disease duration in PD patients. We initially observed that plasma (t)Hcy levels were increased by around 30 % in patients affected by PD compared to controls. Linear correlation, multiple regression and comparative analyses revealed that the major determinant of the increased plasma concentrations of (t)Hcy in PD patients was folic acid deficiency, whereas in controls (t)Hcy levels were mainly determined by plasma vitamin B(12) concentrations. We also observed that alcohol consumption, gender and L-DOPA treatment did not significantly alter plasma (t)Hcy, folic acid and vitamin B(12) levels in parkinsonians. Furthermore, disease duration was positively associated with (t)Hcy levels and smoking was linked with a deficit of folic acid in PD patients. Considering the potential synergistic deleterious effects of Hcy increase and folate deficiency on the central nervous system, we postulate that folic acid should be supplemented to patients affected by PD in order to normalize blood Hcy and folate levels, therefore potentially avoiding these risk factors for neurologic deterioration in this disorder.

Integrity signals

Registry

Crossref · 10.1007/s11011-009-9139-4

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Under-representation of Prevotellaceae diminishes levels of health-promoting neuroactive short chain fatty acids and the capacity for biosynthesis of thiamine and folate, in line with decreased levels of these vitamins in Parkinson's disease patients.

    “The under-representation of Prevotellaceae diminishes the levels of health-promoting neuroactive short chain fatty acids (SCFA) and the capacity for biosynthesis of thiamine and folate (Arumugam et al., 2011), which is in line with decreased levels of these vitamins in PD patients (dos Santos et al., 2009;Luong and Nguyễn, 2013).”

    From The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies (2017) · cites this paper as dos Santos et al., 2009

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
dos Santos, E. F., Busanello, E. N. B., Miglioranza, A., Zanatta, Â., Barchak, A. G., Vargas, C. R., Saute, J., Rosa, C., Carrion, M. J., Camargo, D., Dalbem, A., da Costa, J. C., de Sousa Miguel, S. R. P., de Mello Rieder, C. R., & Wajner, M.
Affiliations
  • Hospital de Clínicas de Porto Alegre (BR)
  • Universidade Federal do Rio Grande do Sul (BR)
  • Pontifícia Universidade Católica do Rio Grande do Sul (BR)
ORCID
Venue
Metabolic Brain Disease
Publisher
Springer Science and Business Media LLC
Published
2009-03-18
Volume
24
Issue
2
Pages
257-269
ISSN
  • 0885-7490 (ISSN-L)
  • 1573-7365
DOI
10.1007/s11011-009-9139-4
OpenAlex
W1997144351
Cited by
76
References
69
Citations by year
2026: 1 · 2025: 3 · 2024: 7 · 2023: 9 · 2022: 6 · 2021: 7 · 2020: 8 · 2019: 7 · 2018: 2 · 2017: 5 · 2016: 1 · 2015: 2 · 2014: 5 · 2012: 4
FWCI
3.07
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Metabolic Brain Disease (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Folate and B Vitamins Research
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
Parkinson's disease, hyperhomocysteinemia, total homocysteine, folate deficiency, vitamin B12, folic acid supplementation, smoking, L-dopa treatment, disease duration, neurodegeneration risk factors
MeSH terms
Analysis of Variance, Female, Folic Acid, Folic Acid Deficiency, Homocysteine, Humans, Levodopa, Male, Middle Aged, Nerve Degeneration, Parkinson Disease, Reference Values, Vitamin B 12, Case-Control Studies, Matched-Pair Analysis, Statistics, Nonparametric, Hyperhomocysteinemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review